Xofluza for Acute Uncomplicated Influenza

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Ruth Carrico, PhD, DNP, APRN, sat down with Drug Topics to discuss the importance of COVID-19 and influenza vaccination.

The drug is also approved to treat schizophrenia and bipolar depression.

“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.

Ruth Carrico, PhD, DNP, APRN, discussed declining influenza and COVID-19 vaccination rates and how it has created a looming threat for public health officials.